Throughout 2021 Relief will continue to evaluate and take steps to facilitate interest from institutional investors. In 
addition, the Company expects to "up list" to a major U.S. stock exchange in the coming months. 
Relief's 2020 Annual Report is available for download at https://relieftherapeutics.com/investor-relations. 
### 
ABOUT RELIEF THERAPEUTICS HOLDING AG 
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in 
human patients or a strong scientific rationale. Relief's lead drug candidate RLF-100^TM (aviptadil), a synthetic form 
of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory 
deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a 
Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of 
ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate 
(NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. 
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB 
under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. 
Follow us on LinkedIn 
CONTACT                                                            FOR MEDIA/INVESTOR INQUIRIES: 
RELIEF THERAPEUTICS Holding AG                                     MC Services AG 
Raghuram (Ram) Selvaraju, Ph.D., MBA                               Anne Hennecke / Brittney Sojeva 
Chairman of the Board                                              Tel.: +49 (0) 211-529-252-14 
Mail: contact@relieftherapeutics.com                               Mail: relief@mc-services.eu Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for ACER-001 for the treatment of UCDs and MSUD, nor whether the ongoing clinical trials of Relief's lead compound, RLF-100(TM) (aviptadil) in advanced clinical development to treat respiratory deficiency due to COVID-19, will be successful. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. -----------------------------------------------------------------------------------------------------------------------

End of Media Release ----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      RELIEF THERAPEUTICS Holdings AG 
              Avenue de Sécheron 15 
              1202 Genève 
              Switzerland 
E-mail:       contact@relieftherapeutics.com 
Internet:     https://relieftherapeutics.com 
ISIN:         CH0100191136 
Listed:       SIX Swiss Exchange 
EQS News ID:  1184903 
 
End of News   EQS Group News Service 
=------------

1184903 2021-04-15

(END) Dow Jones Newswires

April 15, 2021 01:01 ET (05:01 GMT)